New combo therapy aims to stop liver cancer recurrence in High-Risk patients

NCT ID NCT06644937

Recruiting now Disease control Sponsor: Zhujiang Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether combining a liver-directed procedure (TACE) with the drug icaritin can help prevent liver cancer from coming back after surgery in patients at high risk of recurrence. Thirty adults who had their liver cancer completely removed will receive up to 4 TACE treatments plus 6 months of icaritin pills. The main goal is to see how many patients remain cancer-free after one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Icaritin (Acoradine) combined with transcatheter arterial chemoembolization (TACE)
What this could lead to: If it works, this could offer a new way to delay or prevent liver cancer from coming back after surgery in patients at high risk.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply broadly. The combination treatment also carries risks from both TACE and icaritin, and may not improve recurrence rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

Contacts and locations

Locations

Zhujiang Hospital, Southern Medical University
RECRUITING

Guangzhou, Guangdong, 510000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.